403-23-6

Basic information

• Product Name: 2-Fluoro-4-nitrobenzoyl chloride
• Synonyms: 2-Fluoro-4-nitrobenzoyl chloride
• CAS NO: 403-23-6
• Molecular Formula: C₇H₃ClFNO₃
• Molecular Weight: 203.5550232
• Mol File: 403-23-6.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Fluoro-4-nitrobenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-4-nitrobenzoyl chloride(403-23-6)
• EPA Substance Registry System: 2-Fluoro-4-nitrobenzoyl chloride(403-23-6)

Safety Data

• Hazardous Substances Data: 403-23-6(Hazardous Substances Data)

Usage

General Description

2-Fluoro-4-nitrobenzoyl chloride is a chemical compound with the molecular formula C7H3ClFNO3. It is a derivative of benzoyl chloride, with a fluorine and nitro group attached to the benzene ring. 2-Fluoro-4-nitrobenzoyl chloride is a reactive and versatile intermediate in organic synthesis, often used in the production of pharmaceuticals and agrochemicals. It can be used in the synthesis of various heterocyclic compounds and can also be employed as a reagent in organic reactions, such as acylation and amidation. Its unique structure and reactivity make it a valuable building block in the development of new chemical compounds for various applications.

Upstream product

• 1427-07-2 2-fluoro-4-nitrotoluene 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 

Downstream Products

• 350-32-3 2-fluoro-4-nitrobenzamide 
• 1443144-21-5 2-fluoro-4-nitro-N-(quinolin-8-yl)benzamide 
• 915087-33-1 enzalutamide 
• 1289942-66-0 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methyl propanoic acid 
• 1449291-08-0 C₁₀H₈FNO₅ 
• 1439356-66-7 methyl 1-methyl-7-nitro-4-oxo-2-phenyl-1,4-dihydroquinoline-3-carboxylate 
• 1251950-44-3 C₁₃H₁₆FN₃O₄ 
• 1251950-20-5 C₁₃H₁₆FN₃O₃ 
• 1251950-00-1 C₁₂H₁₄FN₃O₃ 
• 1251950-52-3 C₁₁H₁₁FN₂O₄ 

Relevant articles and documents

Benzothiazole compounds and medical application

The invention discloses a benzothiazole compound and medical application thereof, particularly relates to a benzothiazole compound shown as a formula I and medical application thereof, and especiallyrelates to application of the benzothiazole compound serving as a USP7C-terminal structural domain regulating agent in medicines for preventing and treating myelodysplastic syndromes and malignant tumors. The benzothiazole compound shown in the formula I or the pharmaceutically acceptable salt or solvate of the benzothiazole compound has strong binding force with USP7C-terminal protein; and the protein level of DNMT1 in tumor cells can be reduced, so that the compound can be applied to the preparation of USP7 regulators, has a remarkable anti-tumor cell proliferation effect, and can be used for preparing medicines for preventing or treating myelodysplastic syndrome and malignant tumors.

Copper-Mediated Aminoquinoline-Directed Radiofluorination of Aromatic C?H Bonds with K18F

A Cu-mediated ortho-C?H radiofluorination of aromatic carboxylic acids that are protected as 8-aminoquinoline benzamides is described. The method uses K18F and is compatible with a wide range of functional groups. The reaction is showcased in t

Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents

Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145 cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising in vitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.